ReiThera has announced the first healthy volunteer has been dosed in a Phase 1 study of the Company's vaccine candidate (GRAd-COV2) against the novel coronavirus (SARS-CoV-2). The Phase 1 study is being conducted in Italy at the Lazzaro Spallanzani National Institute for Infectious Diseases (INMI) in Rome and at the GB Rossi University Hospital in Verona.
ReiThera's vaccine candidate GRAd-COV2 encodes the full-length spike protein of the SARS-CoV-2 coronavirus. The vaccine technology is based on a novel, proprietary replication-defective gorilla adenoviral (GRAd) vector, which both induced a strong humoral and cellular immune response in preclinical studies and demonstrated a good safety profile. GRAd-COV2 is expected to induce strong immune responses based on low pre-existing immunity to the vector in humans.
Vaccines based on similar simian adenoviral vectors, such as Chimpanzee adenoviral vectors (ChAd), have been evaluated in Phase 1 and 2 clinical trials in other infectious diseases and proved to be safe and immunogenic with a single-dose vaccine.
The Phase 1 clinical trial is evaluating the safety and immunogenicity of GRAd-COV2 in 90 healthy volunteers divided equally into two age cohorts: 18-55 years and 65-85 years. Each cohort will be divided into three study arms of 15 volunteers which will be administered one of three escalating doses of GRAd-COV2. Participants will be monitored over a 24-week period.
The primary objective of the study is to evaluate the safety and tolerability of GRAd-COV2, and to select a vaccine dose for further investigation in a Phase 2/3 trial. The secondary objective is to evaluate the vaccine's ability to induce immune responses (antibodies and T cells) against the novel SARS-CoV-2 coronavirus in volunteers. Interim safety and immunogenicity analysis are expected by mid Q4 2020 which will guide dose selection for Phase 2/3 studies.
A larger international Phase 2/3 trial in countries where SARS-CoV-2 is still very active is planned to commence by the end of 2020, pending positive interim safety and immunogenicity results of the Phase 1 trial.
The Phase 1 trial of GRAd-COV2 is being funded by the Italian Ministry of Scientific Research and the Lazio Region. The study is being run jointly by ReiThera and Lazzaro Spallanzani INMI using initial vaccine material manufactured at ReiThera's cGMP facility in Rome.
In parallel, ReiThera is working with LEUKOCARE in Germany to develop a thermostable GRAd-COV2 vaccine formulation and with Univercells in Belgium to develop a bespoke manufacturing process to enable rapid, large-scale production of the vaccine.
"This study is the first important step in the clinical development of our novel GRAd-COV2 vaccine against COVID-19," said ReiThera's Chief Technology Officer, Stefano Colloca. "We are proud to undertake this trial in Italy where the impact of COVID-19 has been felt particularly hard. The cutting-edge science behind our approach is backed by many years of pioneering research on adenoviral vector technologies with pre-clinical and clinical data generated with a single-dose vaccine in other serious infectious diseases demonstrating potent humoral and cellular immune responses. This feature makes our technology platform suitable for an outbreak situation such as COVID-19 and has clear advantages in terms of manufacturing and compliance."
"The launch of this Phase 1 trial demonstrates ReiThera's expertise and what can be done when stakeholders come together towards a common goal," said ReiThera's Chief Executive Officer, Antonella Folgori. "We are grateful to Lazzaro Spallanzani INMI for their ongoing collaboration and to the Italian Ministry of Scientific Research and the Lazio Region for funding the trial and initial manufacturing of the GRAd-COV2 vaccine candidate. We look forward to providing important updates about the safety and immunogenicity of our vaccine candidate over the coming months, and potentially advancing into international Phase 2/3 trial later in the year."
GRAd-COV2, the candidate vaccine against SARS-CoV-2 recently developed by ReiThera, is based on a novel and proprietary replication-defective simian (gorilla) adenoviral vector...
(All Rights Reserved)